x POMALYST® (pomalidomide) is a thalidomide analogue indicated, in combination with dexamethasone, for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.

See other indications for POMALYST:

This website is intended for U.S. Healthcare Professionals.

This website is best viewed
using the horizontal display
on your tablet device.

This website is best viewed
using the vertical display
on your mobile device.

The second remission is typically
the second longest1-4


Graphic depicting typical disease progression and relapse timing of multiple myeloma

Explore an NCCN Clinical Practice Guidelines
in Oncology (NCCN Guidelines®) recommendation
for progressive disease

See the Recommendation

M-protein, monoclonal protein; NCCN, National Comprehensive Cancer Network.

References: 1. Harousseau JL, Attal M. How I treat first relapse of myeloma. Blood. 2017;130(8):963-973. 2. National Cancer Institute. Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®) – Health Professional Version. Accessed March 2, 2023. 3. Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020;10(9):94. 4. Fernandez de Larrea C, Mailankody S, Landgren O, Smith EL. Future prospects of chimeric antigen receptor T-cell therapy for multiple myeloma. Adv Cell Gene Ther. 2020;3:e72. 5. Kumar SK, Rajkumar V, Kyle RA, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3(17046):1-20. 6. Kumar SK, Therneau TM, Gertz MA, et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc. 2004;79(7):867-874. 7. Usmani S, Ahmadi T, Ng Y, et al. Analysis of real-world data on overall survival in multiple myeloma in patients with ≥3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD. Oncologist. 2016;21(11):1355-1361.